Business Standard

Laurus Labs hits record high on robust September quarter results

The company's Ebitda margins improved 1,349 basis points to 32.8 per cent due to better product mix and improved operating leverage

pharmacy, drugs, medicine, pharma companies, pharmaceuticals, vaccine, coronavirus, covid, testing
Premium

According to virologists, there are four phases to developing a vaccine.

SI Reporter Mumbai
Laurus Labs hit record high of Rs 345 after rising 4.5 per cent on the BSE on Friday after the company reported a robust set of July-September quarter (Q2FY21) numbers. The pharmaceutical company's stock surpassed its previous high of Rs 343.20, touched on October 8, 2020.

At 09:26 am, Laurus Labs had erased its morning gain and was trading 1 per cent higher at Rs 332 on the BSE, as compared to 0.26 per cent rise in the S&P BSE Sensex. A combined 3.5 million equity shares had changed hands in the first 10 minutes of trade on the

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in